ISRCTN12884465进行中（未招募）未知
StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): a randomised, double-masked, sham-controlled, clinical trial comparing low-voltage X-ray irradiation with as needed ranibizumab to as needed ranibizumab monotherapy
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 411
研究概览
简要总结
2016 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/27881184 protocol
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 01/08/2018:
- •1. Participants must have neovascular AMD in the study eye, for which they have received at least three prior intravitreal injections of either bevacizumab (Avastin), aflibercept (Eylea), ranibizumab (Lucentis) or pegaptanib (Macugen)
- •2. Participants must have received an anti-VEGF injection in the study eye within 3 months prior to enrolment
- •3. Participants must require treatment with anti-VEGF therapy at the time of enrolment, due to OCT evidence of subretinal fluid and/or cystoid macular oedema, and have a macular volume that is greater than a pre-defined threshold that varies for each different make of SD-OCT machine
- •4. Participants must be at least 50 years of age
- •Previous participant inclusion criteria:
- •1. Participants must have neovascular AMD in the study eye, for which they have received at least three prior intravitreal injections of either bevacizumab (Avastin), aflibercept (Eylea), ranibizumab (Lucentis) or pegaptanib (Macugen)
- •2. Participants must have received an anti-VEGF injection in the study eye within 3 months prior to enrolment
- •3. Participants must require treatment with anti-VEGF therapy at the time of enrolment, due to OCT evidence of subretinal fluid and/or cystoid macular oedema, and a macular volume that is greater than the 95th percentile of normal for the SD-OCT machines used in the investigational sites
- •4. Participants must be at least 50 years of age
排除标准
- •Current participant exclusion criteria as of 01/08/2018:
- •1. Disciform scarring that involves the fovea, in the study eye
- •2. Visual acuity worse than 6/96 (24 ETDRS letters) in the study eye
- •3. Lesion size greater than 4 mm in greatest linear dimension, or greater than 2 mm from the centre of the fovea to the furthest point on the lesion perimeter
- •4. An axial length of less than 20 mm, or greater than 26 mm, in the study eye
- •5. Contraindication or sensitivity to contact lens application, including recurrent corneal erosions, in the study eye
- •6. Type 1 or Type 2 diabetes mellitus
- •7. Retinopathy in the study eye
- •8. Prior or current therapies in the study eye for age-related macular degeneration, other than anti-VEGF agents, including submacular surgery, subfoveal thermal laser photocoagulation, photodynamic therapy (PDT), or transpupillary thermotherapy (TTT)
- •9. Presence of an intravitreal device in the study eye
- •10. Previous radiation therapy to the study eye, head or neck with the exception of radio-iodine treatment for hyperthyroidism, epimacular brachytherapy to the non-study eye, or Oraya SRT to the non-study eye
- •11. Inadequate pupillary dilation or significant media opacities in the study eye, including cataract, which may interfere with visual acuity testing, the clinical evaluation of the posterior segment, or fundus imaging
- •12. Study eyes with CNV due to causes other than AMD, including presumed ocular histoplasmosis syndrome (POH), angioid streaks, multifocal choroiditis, choroidal rupture, and pathological myopia (greater than 8 Dioptres spherical equivalent). Participants with retinal angiomatous proliferation (RAP) or idiopathic polypoidal choroidal vasculopathy (IPCV) are not excluded
- •13. Known allergy to intravenous fluorescein, ICG or intravitreal ranibizumab
- •14. Intraocular surgery or laser-assisted in situ keratomileusis (LASIK) in the study eye within 12 weeks prior to enrolment
- •15. Prior pars plana vitrectomy in the study eye
- •16. Current participation in another interventional clinical trial, or participation in such a clinical trial within the last six months
- •17. Unwilling, unable, or unlikely to return for scheduled follow-up for the duration of the trial
- •18. Women who are pregnant at the time of radiotherapy
- •19. Participants with an implantable cardioverter defibrillator (ICD) or pacemaker implant (or any implanted device) where the device labelling specifically contraindicates patients undergoing X-ray
- •20. Any other condition, which in the judgment of the investigator, would prevent the participant from granting informed consent or completing the study, such as dementia and mental illness (including generalized anxiety disorder and claustrophobia)
- •Previous participant exclusion criteria:
- •1. Disciform scarring that involves the fovea, in the study eye
- •2. Geographic atrophy that involves the fovea, or an area of geographic atrophy that is more than 500 microns in greatest diameter, immediately adjacent to the fovea, in the study eye
- •3. Visual acuity worse than 6/96 (24 ETDRS letters) in the study eye
- •4. Lesion size greater than 4 mm in greatest linear dimension, or greater than 2 mm from the centre of the fovea to the furthest point on the lesion perimeter
- •5. Distance from the center of the fovea to the nearest edge of the optic disc less than 3 mm in the study eye (this distance is confirmed by the Oraya SRT device software immediately prior to treatment)
- •6. An axial length of less than 20 mm, or greater than 26 mm,
研究者
相似试验
尚未招募
不适用
Indication for stereotactic radiotherapy of the macula with IRay® for wet age-related macular degeneratioH35.3Degeneration of macula and posterior poleDRKS00009593niversitäts-Augenklinik Freiburg800
已完成
2 期
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic MelanomaLiver MetastasesLung MetastasesRecurrent MelanomaStage IV MelanomaTumors Metastatic to BrainNCT02107755Ohio State University Comprehensive Cancer Center8
已完成
2 期
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trialcancer spread to other parts of the bodymetastatic cancer10027476NL-OMON37922Vrije Universiteit Medisch Centrum20
进行中（未招募）
2 期
High dose Radiation therapy to eradicate early metastatic prostate cancer as an alternative to hormone or chemotherapy: a prospective phase II studyProstate CancerACTRN12618000566235Integrated Clinical Oncology Network Pty Ltd (ICON)208
尚未招募
不适用
Mapping guided Stereotactic ablative RadiotherapyNL-OMON27436Departments of Cardiology and Radiotherapy, Leiden University Medical Center12